SPY442.63-1.29 -0.29%
DIA349.92+2.05 0.59%
IXIC14,894.12-153.58 -1.02%

BRIEF-Assembly Bio Announces Decision To Discontinue Clinical Development Of AbI-H2158

reuters.com · 09/01/2021 16:21
BRIEF-Assembly Bio Announces Decision To Discontinue Clinical Development Of AbI-H2158

- Assembly Biosciences Inc ASMB:

  • ASSEMBLY BIO ANNOUNCES DECISION TO DISCONTINUE CLINICAL DEVELOPMENT OF ABI-H2158

  • ASSEMBLY BIO - DECISION TO DISCONTINUE DEVELOPMENT OF ABI-H2158 FOLLOWS OBSERVATION OF ELEVATEDALANINE TRANSAMINASE (ALT) LEVELS IN PHASE 2 STUDY

  • ASSEMBLY BIOSCIENCES INC - COMPANY WILL FOCUS ON ADVANCING ONGOING TRIPLE COMBINATION STUDIES AND EARLIER PIPELINE CANDIDATES

Source text for Eikon: ID:nGNX4VBRxt

Further company coverage: ASMB